Showing results (571-580 of 1,837) with videos related to

Sort By:
Pageof 184
ESMO Open|October 9, 2025
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancerD Tai, T Conroy, J J X Lee, et al.
ESMO Open|October 8, 2025
Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world studyS M Tolaney, L Spring, Y G Abdou, et al.
ESMO Open|October 17, 2025
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapyR Gómez-Bravo, B Walbaum, M Bergamino, et al.
ESMO Open|October 8, 2025
Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in ItalyA Gambella, F Grillo, P Parente, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
ESMO Open|October 1, 2025
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancerK Yamamoto, Y Owaki, I Nakayama, et al.
ESMO Open|September 30, 2025
Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysisS C Yazgan, E Yekedüz, E Akkuş, et al.
ESMO Open|June 25, 2025
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective studyC Catania, S V Liu, M Garassino, et al.
ESMO Open|December 30, 2025
Clinical utility of pleural effusion supernatant cell-free DNA genotyping in previously treated patients with advanced non-small-cell lung cancer and disease progression: a multicenter retrospective studyS-C Chang, C-Y Huang, Y-C Lai, et al.
ESMO Open|December 16, 2025
TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trialS Wang, N Li, Q Cheng, et al.
Pageof 184